SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing extreme volatility as traders react to contradictory reports surrounding potential peace talks between the U.S. and Iran, with the community expressing deep skepticism over perceived market manipulation. Investors remain highly divided, with many debating the credibility of official statements while navigating a chaotic environment driven by conflicting headlines and significant swings in market sentiment.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as traders react to a volatile geopolitical landscape, specifically centered around a potential ceasefire in the Iran conflict and its impact on energy infrastructure. The community is deeply divided, with many debating whether the reported de-escalation is a genuine diplomatic breakthrough or a tactical move intended to manipulate market sentiment and influence oil prices.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The stock is experiencing intense volatility and aggressive community debate as investors react to high-stakes political developments surrounding U.S.-Iran tensions. Discussions are dominated by speculation over market manipulation and the geopolitical implications of administration statements, with market participants closely monitoring potential impacts on global energy sectors.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as traders weigh President Trump's aggressive ultimatum against Iran regarding the closure of the Strait of Hormuz. Community sentiment is deeply divided, with many debating the impact of potential military escalation on energy infrastructure versus speculation that ongoing market manipulation is being used to artificially suppress oil prices.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors digest the major announcement of its acquisition of World View, a move aimed at establishing the company as a scaled defense prime by integrating layered sensing and tactical autonomy. The community is heavily focused on the company's aggressive revenue guidance for 2026, rising backlog, and the shifting narrative from a growth-stage startup to a significant player in the defense sector.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The DIA is currently at the center of a volatile market environment as traders navigate high-stakes geopolitical tensions in the Middle East, surging oil prices, and uncertainty surrounding upcoming FOMC policy decisions. Investors are actively debating the potential for stagflation and the long-term economic impact of the ongoing conflict, leading to sharp polarization between those betting on a relief rally and those bracing for further downside.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following the abrupt resignation of President and CEO Peter Greenleaf and several other key executives, with board chair Kevin Tang assuming the CEO role. Investors are expressing cautious optimism that this leadership shake-up, combined with the new CEO's decision to forgo compensation, may finally clear the path for a potential buyout or significantly improved equity value.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing heightened volatility and intense scrutiny as investors weigh speculative future projects, such as the Terafab chip initiative, against concerns over declining core EV market share and ongoing regulatory challenges. The community remains sharply divided, with bulls pointing to long-term AI and robotics potential while bears emphasize deteriorating fundamentals and the broader geopolitical uncertainty currently roiling global markets.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is experiencing intense volatility as traders closely monitor escalating geopolitical tensions in the Middle East and their potential impact on global energy supplies. The community is actively debating the reliability of market-moving news, with many expressing skepticism toward official narratives and alleging institutional suppression of volatility to prop up major indices.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors scramble to reprice energy assets following major damage to Qatar's LNG infrastructure, fueling fears of a multi-year supply shortage across Europe. The stock is currently the focus of intense retail attention and social media debate, with active discussions centering on the potential for a short squeeze, the firm's strategic position in Italian gas markets, and ongoing geopolitical tensions in the Middle East.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Procyon Advisors LLC Has $7.77 Million Holdings in Eli Lilly and Company $LLY

Procyon Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 176.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,227 shares of the company's stock after purchasing an ad...

Aventura Private Wealth LLC Buys Shares of 3,861 Eli Lilly and Company $LLY

Aventura Private Wealth LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 3,861 shares of the company's stock, valued at approximately $4,150,000. Eli Lilly and Company...

Pharmaceutical Stocks Worth Watching - March 22nd

Abbott Laboratories, AbbVie, and Eli Lilly and Company are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, and sell prescription drugs and related medical products, givi...

Should You Buy Eli Lilly Stock Before April 10?

Key PointsEli Lilly dominates the U.S. weight loss drug market...

Sagespring Wealth Partners LLC Has $10.59 Million Stake in Eli Lilly and Company $LLY

Sagespring Wealth Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent filing with the...

Everhart Financial Group Inc. Buys 1,132 Shares of Eli Lilly and Company $LLY

Everhart Financial Group Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,574 shares of the company's stock after acquiring an additional 1,132 s...

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


Top Pharmaceutical Stocks To Research - March 21st

Abbott Laboratories, AbbVie, Eli Lilly and Company, Bristol Myers Squibb, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Medical Stocks To Watch Today - March 21st

UnitedHealth Group, Abbott Laboratories, AbbVie, Eli Lilly and Company, and Merck & Co., Inc. are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

Union Bancaire Privee UBP SA Sells 3,199 Shares of Eli Lilly and Company $LLY

Union Bancaire Privee UBP SA trimmed its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LLY News

LLYLilly(Eli) & Co